Categories: HealthcareNews

Health Rosetta Hosts the 2nd Annual 2024 Rosie Awards at RosettaFest

Health Rosetta Awards Rosie Awards to 80+ Companies for Outstanding Healthcare Leadership

WASHINGTON, DC / ACCESSWIRE / September 12, 2024 / Health Rosetta, an ecosystem for replicating adoption of practical non-partisan fixes to our health care system, will host the prestigious Rosie Awards at RosettaFest 2024, celebrating outstanding contributions and innovative leadership in the healthcare sector, at 5 p.m. Thursday, Sept. 12, at the distinguished JW Marriott in Washington, D.C.

Over 80 companies from across the nation were selected from a pool of 196 finalists and 2,000+ initial candidates nominated by benefits advisors, solution providers, and clinicians in a competitive process. Award winners will be recognized for meeting the following criteria: high Plan Grader™ score, effective use of their “Health Rosetta Dividend,” collaborative spirit, and an abundance mindset.

Honoring Excellence in Healthcare

The Plan Grader™ is an independent assessment tool evaluating health plan strategies, assisting organizations in lowering costs and enhancing benefits over a 2-3 year period through actionable insights. Each Rosie Award winner has eliminated a portion of the over $1 trillion in industry waste and reinvested those resources back into their organization or community, which is known as the Health Rosetta Dividend.

“It’s exciting that people have these plans that produce great health outcomes, but what’s even more remarkable is how these companies are using these savings to not only reduce premiums and eliminate copays, but also fund college tuition, subsidize healthy foods, home solar, exercise classes and more to improve the lives of their employees,” says Dave Chase, creator and co-founder of Health Rosetta.

The Health Rosetta Dividend is essential because “despite spending trillions of dollars, our healthcare system has left 100 million Americans in debt. The cost of care has become a leading cause of death due to half of Americans avoiding care because of cost,” remarks Chase. The Community Owned Health Plans (COHPs) based on Health Rosetta principles begin with one employer, providing preventive care that has the potential to eliminate the epidemic of medical debt in America and it embodies transparency and ethics, protecting patients from hidden costs.

Celebrating Each Winner’s Visionary Approach

Each winner highlights the award-winning plan design and advice led by their Health Rosetta Advisor who championed the development and implementation of health plans for better health outcomes at a reduced cost. Health Rosetta is proud to celebrate and recognize these exceptional advisors and companies, leading the charge with the best health plans in America.

“This new healthcare economy is about freedom – freedom from financial burdens, bureaucratic constraints, and to create a system that truly serves its people,” said Chase.

About the Rosie Awards and Health Rosetta

The Rosie Awards, presented by Health Rosetta, honor those who are passionately working to realize the future of health in action. For more information about Health Rosetta, the Plan Grader or the Rosie Awards, contact Dave Chase, creator and co-founder of Health Rosetta, at dave.chase@healthrosetta.org or find a Health Rosetta Advisor in your community at https://healthrosetta.org/map.

Contact Information

Dave Chase
Creator and Co-founder
dave.chase@healthrosetta.org

SOURCE: Health Rosetta

View the original press release on newswire.com.

Staff

Recent Posts

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate…

5 hours ago

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for…

5 hours ago

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

5 hours ago

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one…

5 hours ago

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed…

5 hours ago